Sirtex cancer treatment added to ESMO guidelines

By staff writers

October 12, 2016 -- Cancer treatment firm Sirtex Medical said the European Society of Medical Oncology (ESMO) has included the company's yttrium-90 (Y-90) microspheres as an option in new guidelines for the treatment of intrahepatic cholangiocarcinoma (iCCA).

Specifically, ESMO said selective internal radiation therapy (SIRT) using Y-90 microspheres may be considered as an option for postchemotherapy treatment of iCCA. The full ESMO biliary cancer treatment guidelines were published in September as a supplement to the Annals of Oncology.

Copyright © 2016

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking